Detalhe da pesquisa
1.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36737752
2.
Antiandrogens as Therapies for COVID-19: A Systematic Review.
Cancers (Basel)
; 16(2)2024 Jan 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38254788
3.
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Ther Adv Med Oncol
; 15: 17588359231156147, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36895852